Atsufumi Kawabata

List of Publications by Year
in descending order

209 papers	6,290 citations	61984 43 h-index	102487 66 g-index
221 all docs	221 docs citations	221 times ranked	4753 citing authors

#	Article	IF	Citations
1	Role of neuron-derived ATP in paclitaxel-induced HMGB1 release from macrophages and peripheral neuropathy. Journal of Pharmacological Sciences, 2022, 148, 156-161.	2.5	5
2	Development of hepatic impairment aggravates chemotherapy-induced peripheral neuropathy following oxaliplatin treatment: Evidence from clinical and preclinical studies. Journal of Pharmacological Sciences, 2022, 148, 315-325.	2.5	2
3	Role of highâ€mobility group box 1 and its modulation by thrombomodulin/thrombin axis in neuropathic and inflammatory pain. British Journal of Pharmacology, 2021, 178, 798-812.	5.4	21
4	Effects of Bepridil and Pimozide, Existing Medicines Capable of Blocking T-Type Ca²⁺ Channels, on Visceral Pain in Mice. Biological and Pharmaceutical Bulletin, 2021, 44, 461-464.	1.4	6
5	Estrogen decline is a risk factor for paclitaxel-induced peripheral neuropathy: Clinical evidence supported by a preclinical study. Journal of Pharmacological Sciences, 2021, 146, 49-57.	2.5	14
6	Macrophage as a Peripheral Pain Regulator. Cells, 2021, 10, 1881.	4.1	63
7	Development of diabetes mellitus following hormone therapy in prostate cancer patients is associated with early progression to castration resistance. Scientific Reports, 2021, 11, 17157.	3.3	0
8	Caspase-Dependent HMGB1 Release from Macrophages Participates in Peripheral Neuropathy Caused by Bortezomib, a Proteasome-Inhibiting Chemotherapeutic Agent, in Mice. Cells, 2021, 10, 2550.	4.1	7
9	Itch and pain caused by intradermal injection of sulfides in mouse cheek: Effect of genetic deletion of Ca‹sub›v‹/sub›3.2 T-type calcium channels. Proceedings for Annual Meeting of the Japanese Pharmacological Society, 2021, 94, 3-P1-08.	0.0	0
10	Role of HMGB1 in Chemotherapy-Induced Peripheral Neuropathy. International Journal of Molecular Sciences, 2021, 22, 367.	4.1	17
11	Identification of Remaining Life Expectancy Less Than Two Weeks by C-Reactive Protein/Albumin Ratio, Prognostic Nutritional Index, Fibrosis-4 Index, and Albumin-Bilirubin Score in Terminal Cancer Patients. Journal of Palliative Medicine, 2021, , .	1.1	1
12	Risk factors and pharmacotherapy for chemotherapy-induced peripheral neuropathy in paclitaxel-treated female cancer survivors: A retrospective study in Japan. PLoS ONE, 2021, 16, e0261473.	2.5	8
13	Essential role of Cav3.2 T-type calcium channels in butyrate-induced colonic pain and nociceptor hypersensitivity in mice. European Journal of Pharmacology, 2020, 887, 173576.	3.5	4
14	Cystitis-Related Bladder Pain Involves ATP-Dependent HMGB1 Release from Macrophages and Its Downstream H2S/Cav3.2 Signaling in Mice. Cells, 2020, 9, 1748.	4.1	27
15	Cav3.2 overexpression in L4 dorsal root ganglion neurons after L5 spinal nerve cutting involves Egr-1, USP5 and HMGB1 in rats: An emerging signaling pathway for neuropathic pain. European Journal of Pharmacology, 2020, 888, 173587.	3.5	17
16	HMGB1 and its membrane receptors as therapeutic targets in an intravesical substance P-induced bladder pain syndrome mouse model. Journal of Pharmacological Sciences, 2020, 143, 112-116.	2.5	6
17	Tacrolimus, a calcineurin inhibitor, promotes capsaicin-induced colonic pain in mice. Journal of Pharmacological Sciences, 2020, 143, 60-63.	2.5	1
18	A Combination of Cryopreservation and Kneading Maintains the Usability of Mohs Paste. Chemical and Pharmaceutical Bulletin, 2020, 68, 516-519.	1.3	0

#	Article	IF	Citations
19	Changes in Percutaneous Absorption of Fentanyl Patches in Rats Treated with a Sebum-Like Secretion. Chemical and Pharmaceutical Bulletin, 2020, 68, 879-884.	1.3	1
20	Middle molecular weight heparinylphenylalanine, an RAGE blocker, prevents oxaliplatin-induced peripheral neuropathy and butyrate-induced colonic pain in mice. Proceedings for Annual Meeting of the Japanese Pharmacological Society, 2020, 93, 1-P-022.	0.0	0
21	NNC 55-0396, a T-type calcium channel blocker, protects against the brain injury induced by middle cerebral artery occlusion and reperfusion in mice. Journal of Pharmacological Sciences, 2019, 140, 193-196.	2.5	5
22	Role of non-macrophage cell-derived HMGB1 in oxaliplatin-induced peripheral neuropathy and its prevention by the thrombin/thrombomodulin system in rodents: negative impact of anticoagulants. Journal of Neuroinflammation, 2019, 16, 199.	7.2	35
23	Genetic deletion of Cav3.2ÂT-type calcium channels abolishes H2S-dependent somatic and visceral pain signaling in C57BL/6 mice. Journal of Pharmacological Sciences, 2019, 140, 310-312.	2.5	14
24	Prenylflavanones as Novel T-Type Calcium Channel Blockers Useful for Pain Therapy. Natural Product Communications, 2019, 14, 1934578X1987344.	0.5	2
25	Dietary ascorbic acid restriction in GNL/SMP30-knockout mice unveils the role of ascorbic acid in regulation of somatic and visceral pain sensitivity. Biochemical and Biophysical Research Communications, 2019, 511, 705-710.	2.1	3
26	The C-Reactive Protein/Albumin Ratio is Useful for Predicting Short-Term Survival in Cancer and Noncancer Patients. Journal of Palliative Medicine, 2019, 22, 532-537.	1.1	23
27	Critical role of Cav3.2 T-type calcium channels in the peripheral neuropathy induced by bortezomib, a proteasome-inhibiting chemotherapeutic agent, in mice. Toxicology, 2019, 413, 33-39.	4.2	42
28	Regulation of Ca_v3.2-mediated pain signals by hydrogen sulfide. Proceedings for Annual Meeting of the Japanese Pharmacological Society, 2019, 92, 2-S17-3.	0.0	0
29	Role of macrophageâ€“derived HMGB1 as an algogenic molecule â¸ therapeutic target in visceral pain. Pain Research, 2019, 34, 24-30.	0.1	0
30	Evaluation of Transdermal Penetration in Fentanyl Tape Using Franz Diffusion Cells: Changes in Drug Release and Skin Permeation under the Hyperthermia. Iryo Yakugaku (Japanese Journal of) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 297 Td	0.0	0
31	Involvement of the cystathionine-Î³-lyase/Cav3.2 pathway in substance P-induced bladder pain in the mouse, a model for nonulcerative bladder pain syndrome. Neuropharmacology, 2018, 133, 254-263.	4.1	10
32	Prostanoid-dependent bladder pain caused by proteinase-activated receptor-2 activation in mice: Involvement of TRPV1 and T-type Ca 2+ channels. Journal of Pharmacological Sciences, 2018, 136, 46-49.	2.5	5
33	Role of Thrombin in Soluble Thrombomodulin-Induced Suppression of Peripheral HMGB1-Mediated Allodynia in Mice. Journal of NeuroImmune Pharmacology, 2018, 13, 179-188.	4.1	10
34	Involvement of <scp>NF</scp>â€ºB in the upregulation of cystathionineâ€Î³â€lyase, a hydrogen sulfideâ€forming enzyme, and bladder pain accompanying cystitis in mice. Clinical and Experimental Pharmacology and Physiology, 2018, 45, 355-361.	1.9	10
35	Human soluble thrombomodulin-induced blockade of peripheral HMGB1-dependent allodynia in mice requires both the lectin-like and EGF-like domains. Biochemical and Biophysical Research Communications, 2018, 495, 634-638.	2.1	14
36	Zinc deficiency promotes cystitis-related bladder pain by enhancing function and expression of Cav3.2 in mice. Toxicology, 2018, 393, 102-112.	4.2	19

#	Article	IF	Citations
37	Paclitaxel-induced HMGB1 release from macrophages and its implication for peripheral neuropathy in mice: Evidence for a neuroimmune crosstalk. Neuropharmacology, 2018, 141, 201-213.	4.1	61
38	Involvement of Voltage-Gated Calcium Channels in Inflammation and Inflammatory Pain. Biological and Pharmaceutical Bulletin, 2018, 41, 1127-1134.	1.4	42
39	Design and synthesis of novel anti-hyperalgesic agents based on 6-prenylnaringenin as the T-type calcium channel blockers. Bioorganic and Medicinal Chemistry, 2018, 26, 4410-4427.	3.0	13
40	Blockade of T-type calcium channels by 6-prenylnaringenin, a hop component, alleviates neuropathic and visceral pain in mice. Neuropharmacology, 2018, 138, 232-244.	4.1	24
41	Middle molecular weight heparinylphenylalanine is an analgesic with reduced risk of hemorrhage. Proceedings for Annual Meeting of the Japanese Pharmacological Society, 2018, WCP2018, PO3-2-14.	0.0	0
42	High mobility group box 1 suppresses smooth muscle tension in rat aorta via Toll-like receptor 4-dependent upregulation of iNOS. Proceedings for Annual Meeting of the Japanese Pharmacological Society, 2018, WCP2018, PO4-2-28.	0.0	0
43	High glucose induces N-linked glycosylation-mediated functional upregulation and overexpression of Cav3.2 T-type calcium channels in neuroendocrine-like differentiated human prostate cancer cells. Journal of Pharmacological Sciences, 2017, 133, 57-60.	2.5	8
44	Enhanced Hyperthermic Responses to Lipopolysaccharide in Mice Exposed to Repeated Cold Stress. Pharmacology, 2017, 99, 172-178.	2.2	3
45	Repeated Cold Stress Reduces Cyclophosphamide-Induced Cystitis/Bladder Pain and Macrophage Activity in Mice. Pharmacology, 2017, 99, 286-290.	2.2	2
46	Hydrogen Sulfide and T-Type Ca²⁺ Channels in Pain Processing, Neuronal Differentiation and Neuroendocrine Secretion. Pharmacology, 2017, 99, 196-203.	2.2	21
47	Tacrolimus Triggers Transient Receptor Potential Vanilloid-1-Dependent Relapse of Pancreatitis-Related Pain in Mice. Pharmacology, 2017, 99, 281-285.	2.2	5
48	Macrophage-derived HMGB1 as a Pain Mediator in the Early Stage of Acute Pancreatitis in Mice: Targeting RAGE and CXCL12/CXCR4 Axis. Journal of NeuroImmune Pharmacology, 2017, 12, 693-707.	4.1	41
49	Repeated Cold Stress Enhances the Acute Restraint Stress-Induced Hyperthermia in Mice. Biological and Pharmaceutical Bulletin, 2017, 40, 11-16.	1.4	13
50	Circadian pharmacokinetics and limited sampling strategy of everolimus in heart transplant patients. International Journal of Clinical Pharmacology and Therapeutics, 2017, 55, 1-8.	0.6	1
51	Therapeutic potential of RQ-00311651, a novel T-type Ca2+ channel blocker, in distinct rodent models for neuropathic and visceral pain. Pain, 2016, 157, 1655-1665.	4.2	30
52	Involvement of high mobility group box 1 in the development and maintenance of chemotherapy-induced peripheral neuropathy in rats. Toxicology, 2016, 365, 48-58.	4.2	39
53	Endogenous Hydrogen Sulfide Enhances Cell Proliferation of Human Gastric Cancer AGS Cells. Biological and Pharmaceutical Bulletin, 2016, 39, 887-890.	1.4	33
54	Selective sensitization of C-fiber nociceptors by hydrogen sulfide. Journal of Pharmacological Sciences, 2016, 130, 38-41.	2.5	1

#	Article	IF	Citations
55	The prostaglandin E2/EP4 receptor/cyclic AMP/T-type Ca2+ channel pathway mediates neuritogenesis in sensory neuron-like ND7/23 cells. Journal of Pharmacological Sciences, 2016, 130, 177-180.	2.5	16
56	Peripheral HMGB1-induced hyperalgesia in mice: Redox state-dependent distinct roles of RAGE and TLR4. Journal of Pharmacological Sciences, 2016, 130, 139-142.	2.5	40
57	Roles of Ca_v3.2 and TRPA1 channels targeted by hydrogen sulfide in pancreatic nociceptive processing in mice with or without acute pancreatitis. Journal of Neuroscience Research, 2015, 93, 361-369.	2.9	29
58	Intravenous Administration of Cilostazol Nanoparticles Ameliorates Acute Ischemic Stroke in a Cerebral Ischemia/Reperfusion-Induced Injury Model. International Journal of Molecular Sciences, 2015, 16, 29329-29344.	4.1	36
59	Mechanisms for proteinase-activated receptor 1-triggered prostaglandin E₂ generation in mouse osteoblastic MC3T3-E1 cells. Biological Chemistry, 2015, 396, 153-162.	2.5	10
60	Polaprezinc attenuates cyclophosphamide-induced cystitis and related bladder pain in mice. Journal of Pharmacological Sciences, 2015, 127, 223-228.	2.5	16
61	H2S and Pain: A Novel Aspect for Processing of Somatic, Visceral and Neuropathic Pain Signals. Handbook of Experimental Pharmacology, 2015, 230, 217-230.	1.8	21
62	Hydrogen sulfide and neuronal differentiation: Focus on Ca2+ channels. Nitric Oxide - Biology and Chemistry, 2015, 46, 50-54.	2.7	19
63	Functional upregulation of the H2S/Cav3.2 channel pathway accelerates secretory function in neuroendocrine-differentiated human prostate cancer cells. Biochemical Pharmacology, 2015, 97, 300-309.	4.4	26
64	Ouabain exerts cytoprotection by diminishing the intracellular K+ concentration increase caused by distinct stimuli in human leukemic cells. Journal of Pharmacy and Pharmacology, 2014, 67, 126-132.	2.4	1
65	Endogenous and exogenous hydrogen sulfide facilitates T-type calcium channel currents in Cav3.2-expressing HEK293 cells. Biochemical and Biophysical Research Communications, 2014, 445, 225-229.	2.1	52
66	Bladder pain relief by HMGB1 neutralization and soluble thrombomodulin in mice with cyclophosphamide-induced cystitis. Neuropharmacology, 2014, 79, 112-118.	4.1	42
67	Recombinant human soluble thrombomodulin prevents peripheral <scp>HMGB</scp>1â€dependent hyperalgesia in rats. British Journal of Pharmacology, 2013, 170, 1233-1241.	5.4	34
68	<scp>AKAP</scp>â€dependent sensitization of <scp>Ca</scp>_v3.2 channels via the <scp>EP</scp>₄ receptor/c<scp>AMP</scp> pathway mediates <scp>PGE</scp>₂â€induced mechanical hyperalgesia. British Journal of Pharmacology, 2013, 168, 734-745.	5.4	27
69	T-type Calcium Channels: Functional Regulation and Implication in Pain Signaling. Journal of Pharmacological Sciences, 2013, 122, 244-250.	2.5	69
70	Inhibition by Hydrogen Sulfide of Rabbit Platelet Aggregation and Calcium Mobilization. Biological and Pharmaceutical Bulletin, 2013, 36, 1278-1282.	1.4	21
71	Antihyperalgesic Effect of Buprenorphine Involves Nociceptin/Orphanin FQ Peptideâ€“Receptor Activation in Rats With Spinal Nerve Injuryâ€“Induced Neuropathy. Journal of Pharmacological Sciences, 2013, 122, 51-54.	2.5	11
72	Contribution of TRPA1 as a Downstream Signal of Proteinase-Activated Receptor-2 to Pancreatic Pain. Journal of Pharmacological Sciences, 2013, 123, 284-287.	2.5	20

#	Article	IF	Citations
73	Roles of the Hydrogen Sulfide/T-Type Calcium Channel System in Somatic and Visceral Pain Processing. Frontiers of Gastrointestinal Research, 2012, , 212-218.	0.1	0
74	Colonic Hydrogen Sulfide^|^ndash;Induced Visceral Pain and Referred Hyperalgesia Involve Activation of Both Cav3.2 and TRPA1 Channels in Mice. Journal of Pharmacological Sciences, 2012, 119, 293-296.	2.5	45
75	Involvement of the endogenous hydrogen sulfide/Ca_v3.2 Tâ€type Ca²⁺ channel pathway in cystitisâ€related bladder pain in mice. British Journal of Pharmacology, 2012, 167, 917-928.	5.4	64
76	Topical application of disodium isostearyl 2â€Oâ€Lâ€ascorbyl phosphate, an amphiphilic ascorbic acid derivative, reduces neuropathic hyperalgesia in rats. British Journal of Pharmacology, 2012, 166, 1058-1068.	5.4	15
77	Hydrogen sulfideâ€induced mechanical hyperalgesia and allodynia require activation of both Ca_v3.2 and TRPA1 channels in mice. British Journal of Pharmacology, 2012, 166, 1738-1743.	5.4	76
78	Involvement of ERK in NMDA receptor-independent cortical neurotoxicity of hydrogen sulfide. Biochemical and Biophysical Research Communications, 2011, 414, 727-732.	2.1	23
79	Chelating luminal zinc mimics hydrogen sulfide-evoked colonic pain in mice: possible involvement of T-type calcium channels. Neuroscience, 2011, 181, 257-264.	2.3	60
80	Prostaglandin E2 and Pain-An Update. Biological and Pharmaceutical Bulletin, 2011, 34, 1170-1173.	1.4	267
81	Lipid Mediators and Pain Signaling Foreword. Biological and Pharmaceutical Bulletin, 2011, 34, 1153.	1.4	3
82	ONO-8130, a selective prostanoid EP1 receptor antagonist, relieves bladder pain in mice with cyclophosphamide-induced cystitis. Pain, 2011, 152, 1373-1381.	4.2	50
83	Delayed production of arachidonic acid contributes to the delay of proteinaseâ€activated receptorâ€1 (PAR1)â€triggered prostaglandin E₂ release in rat gastric epithelial RGM1 cells. Journal of Cellular Biochemistry, 2011, 112, 909-915.	2.6	5
84	Curcumin Inhibits the Proteinase-Activated Receptor-2â€“Triggered Prostaglandin E2 Production by Suppressing Cyclooxygenase-2 Upregulation and Akt-Dependent Activation of Nuclear Factor-ÎºB in Human Lung Epithelial Cells. Journal of Pharmacological Sciences, 2010, 114, 225-229.	2.5	29
85	Upregulation of Cav3.2 T-type calcium channels targeted by endogenous hydrogen sulfide contributes to maintenance of neuropathic pain. Pain, 2010, 150, 183-191.	4.2	114
86	Phosphorylation of ERK in the spinal dorsal horn following pancreatic pronociceptive stimuli with proteinaseâ€activated receptorâ€2 agonists and hydrogen sulfide in rats: Evidence for involvement of distinct mechanisms. Journal of Neuroscience Research, 2010, 88, 3198-3205.	2.9	21
87	Opposite effects of two thiazolidinediones, ciglitazone and troglitazone, on proteinase-activated receptor-1-triggered prostaglandin E2 release. Toxicology, 2010, 268, 40-45.	4.2	1
88	Involvement of Src kinase in Tâ€type calcium channelâ€dependent neuronal differentiation of NG108â€15 cells by hydrogen sulfide. Journal of Neurochemistry, 2010, 114, 512-519.	3.9	28
89	The proteinase/proteinase-activated receptor-2/transient receptor potential vanilloid-1 cascade impacts pancreatic pain in mice. Life Sciences, 2010, 87, 643-650.	4.3	18
90	Hydrogen sulfide evokes neurite outgrowth and expression of highâ€voltageâ€activated Ca²⁺ currents in NG108â€15 cells: involvement of Tâ€type Ca²⁺ channels. Journal of Neurochemistry, 2009, 108, 676-684.	3.9	46

#	Article	IF	Citations
91	Rhodanese, but not cystathionine-Î³-lyase, is associated with dextran sulfate sodium-evoked colitis in mice: A sign of impaired colonic sulfide detoxification?. Toxicology, 2009, 264, 96-103.	4.2	28
92	Hyperalgesia induced by spinal and peripheral hydrogen sulfide: Evidence for involvement of Cav3.2 T-type calcium channels. Pain, 2009, 142, 127-132.	4.2	125
93	Proteinase-Activated Receptor-2â€"Triggered Prostaglandin E2 Release, but Not Cyclooxygenase-2 Upregulation, Requires Activation of the Phosphatidylinositol 3â€"Kinase / Akt / Nuclear Factor-ÎºB Pathway in Human Alveolar Epithelial Cells. Journal of Pharmacological Sciences, 2009, 111, 269-275.	2.5	20
94	Evidence that PAR2â€triggered prostaglandin E₂ (PGE₂) formation involves the ERKâ€cytosolic phospholipase A₂â€COXâ€1â€microsomal PGE synthaseâ€1 cascade in human lung epithelial cells. Cell Biochemistry and Function, 2008, 26, 279-282.	2.9	15
95	Gastrointestinal roles for proteinaseâ€activated receptors in health and disease. British Journal of Pharmacology, 2008, 153, S230-40.	5.4	76
96	Signal transduction for formation/release of interleukin-8 caused by a PAR2-activating peptide in human lung epithelial cells. Regulatory Peptides, 2008, 145, 42-48.	1.9	16
97	PAR2 triggers IL-8 release via MEK/ERK and PI3-kinase/Akt pathways in GI epithelial cells. Biochemical and Biophysical Research Communications, 2008, 377, 622-626.	2.1	44
98	Basic and Translational Research on Proteinase-Activated Receptors: Preface. Journal of Pharmacological Sciences, 2008, 108, 406-407.	2.5	2
99	Hydrogen Sulfide Causes Relaxation in Mouse Bronchial Smooth Muscle. Journal of Pharmacological Sciences, 2007, 104, 392-396.	2.5	63
100	Hydrogen sulfide as a novel nociceptive messenger. Pain, 2007, 132, 74-81.	4.2	166
101	Roles for H2S in pain processing: Response to Cunha and Verri. Pain, 2007, 130, 302-303.	4.2	0
102	The proteinase inhibitor camostat mesilate suppresses pancreatic pain in rodents. Life Sciences, 2007, 80, 1999-2004.	4.3	27
103	Direct inhibition of endothelial nitric oxide synthase by hydrogen sulfide: Contribution to dual modulation of vascular tension. Toxicology, 2007, 232, 138-146.	4.2	166
104	Hydrogen sulfide inhibits activity of three isoforms of recombinant nitric oxide synthase. Toxicology, 2007, 241, 92-97.	4.2	99
105	Mechanisms for prostaglandin E2 formation caused by proteinase-activated receptor-1 activation in rat gastric mucosal epithelial cells. Biochemical Pharmacology, 2007, 73, 103-114.	4.4	19
106	Dual modulation of the tension of isolated gastric artery and gastric mucosal circulation by hydrogen sulfide in rats. Inflammopharmacology, 2007, 15, 288-292.	3.9	39
107	Proteinase-activated receptors in the gastrointestinal system: a functional linkage to prostanoids. Inflammopharmacology, 2007, 15, 246-251.	3.9	16
108	A protective role of hydrogen sulfide against oxidative stress in rat gastric mucosal epithelium. Toxicology, 2007, 241, 11-18.	4.2	110

#	Article	IF	Citations
109	Colonic hyperalgesia triggered by proteinase-activated receptor-2 in mice: Involvement of endogenous bradykinin. Neuroscience Letters, 2006, 402, 167-172.	2.1	31
110	Mechanisms for modulation of mouse gastrointestinal motility by proteinase-activated receptor (PAR)-1 and -2 in vitro. Life Sciences, 2006, 78, 950-957.	4.3	19
111	Antiallodynic effect of etidronate, a bisphosphonate, in rats with adjuvant-induced arthritis: Involvement of ATP-sensitive K+ channels. Neuropharmacology, 2006, 51, 182-190.	4.1	18
112	Suppression of pancreatitisâ€related allodynia/hyperalgesia by proteinaseâ€activated receptorâ€2 in mice. British Journal of Pharmacology, 2006, 148, 54-60.	5.4	47
113	Distinct Activity of Peptide Mimetic Intracellular Ligands (Pepducins) for Proteinase-Activated Receptor-1 in Multiple Cells/Tissues. Annals of the New York Academy of Sciences, 2006, 1091, 445-459.	3.8	31
114	Physiology and Pathophysiology of Proteinase-Activated Receptors (PARs): PARs in the Respiratory System: Cellular Signaling and Physiological/Pathological Roles. Journal of Pharmacological Sciences, 2005, 97, 20-24.	2.5	60
115	Physiology and Pathophysiology of Proteinase-Activated Receptors (PARs): PAR-2 as a Potential Therapeutic Target. Journal of Pharmacological Sciences, 2005, 97, 38-42.	2.5	35
116	2-Furoyl-LIGRL-NH2 , a potent agonist for proteinase-activated receptor-2, as a gastric mucosal cytoprotective agent in mice. British Journal of Pharmacology, 2005, 144, 212-219.	5.4	31
117	Binding of a highly potent protease-activated receptor-2 (PAR2) activating peptide, [3 H]2-furoyl-LIGRL-NH2 , to human PAR2. British Journal of Pharmacology, 2005, 145, 255-263.	5.4	26
118	Signal Transduction for Proteinase-Activated Receptor-2-Triggered Prostaglandin E2 Formation in Human Lung Epithelial Cells. Journal of Pharmacology and Experimental Therapeutics, 2005, 315, 576-589.	2.5	49
119	Potent and Metabolically Stable Agonists for Protease-Activated Receptor-2: Evaluation of Activity in Multiple Assay Systems in Vitro and in Vivo. Journal of Pharmacology and Experimental Therapeutics, 2004, 309, 1098-1107.	2.5	65
120	Proteinase-Activated Receptor-2-Mediated Relaxation in Mouse Tracheal and Bronchial Smooth Muscle: Signal Transduction Mechanisms and Distinct Agonist Sensitivity. Journal of Pharmacology and Experimental Therapeutics, 2004, 311, 402-410.	2.5	37
121	Distinct roles for protease-activated receptors 1 and 2 in vasomotor modulation in rat superior mesenteric artery. Cardiovascular Research, 2004, 61, 683-692.	3.8	25
122	A protective role of protease-activated receptor 1 in rat gastric mucosa. Gastroenterology, 2004, 126, 208-219.	1.3	45
123	The potent inducible nitric oxide synthase inhibitor ONO-1714 inhibits neuronal NOS and exerts antinociception in rats. Neuroscience Letters, 2004, 365, 111-115.	2.1	19
124	Receptor-activating peptides for PAR-1 and PAR-2 relax rat gastric artery via multiple mechanisms. Life Sciences, 2004, 75, 2689-2702.	4.3	16
125	Activation of trigeminal nociceptive neurons by parotid PAR-2 activation in rats. NeuroReport, 2004, 15, 1617-1621.	1.2	17
126	Impact of a Pharmacist-Implemented Anemia Management in Outpatients with End-Stage Renal Disease in Japan. Biological and Pharmaceutical Bulletin, 2004, 27, 1831-1833.	1.4	23

#	Article	IF	Citations
127	Modulation of Capsaicin-Evoked Visceral Pain and Referred Hyperalgesia by Protease-Activated Receptors 1 and 2. Journal of Pharmacological Sciences, 2004, 94, 277-285.	2.5	58
128	Protease-Activated Receptors (PARs) as Therapeutic Targets: Development of Agonists / Antagonists and Modulation of Gastrointestinal Functions. Drug Design Reviews Online, 2004, 1, 287-296.	0.7	8
129	Modulation of gastric function by proteinase-activated receptors. Drug Development Research, 2003, 60, 9-13.	2.9	6
130	Pain Information Pathways from the Periphery to the Cerebral Cortex. ChemInform, 2003, 34, no.	0.0	0
131	Involvement of EDHF in the hypotension and increased gastric mucosal blood flow caused by PAR-2 activation in rats. British Journal of Pharmacology, 2003, 140, 247-254.	5.4	29
132	Gastrointestinal functions of proteinase-activated receptors. Life Sciences, 2003, 74, 247-254.	4.3	64
133	Effect of a potent iNOS inhibitor (ONO-1714) on acetaminophen-induced hepatotoxicity in the rat. Life Sciences, 2003, 74, 793-802.	4.3	35
134	The PAR-1-activating peptide facilitates pepsinogen secretion in rats. Peptides, 2003, 24, 1449-1451.	2.4	13
135	Gastrointestinal functions of proteinase-activated receptors. Life Sciences, 2003, 74, 247-247.	4.3	8
136	PAR-2: structure, function and relevance to human diseases of the gastric mucosa. Expert Reviews in Molecular Medicine, 2002, 4, 1-17.	3.9	37
137	Capsazepine Inhibits Thermal Hyperalgesia but Not Nociception Triggered by Protease-Activated Receptor-2 in Rats. The Japanese Journal of Pharmacology, 2002, 89, 184-187.	1.2	28
138	Specific expression of spinal Fos after PAR-2 stimulation in mast cell-depleted rats. NeuroReport, 2002, 13, 511-514.	1.2	24
139	Protease-activated receptor-2 (PAR-2) in the pancreas and parotid gland: Immunolocalization and involvement of nitric oxide in the evoked amylase secretion. Life Sciences, 2002, 71, 2435-2446.	4.3	64
140	The PAR-1-activating peptide attenuates carrageenan-induced hyperalgesia in rats. Peptides, 2002, 23, 1181-1183.	2.4	36
141	Role of N-methyl-d-aspartate receptors and the nitric oxide pathway in nociception/hyperalgesia elicited by protease-activated receptor-2 activation in mice and rats. Neuroscience Letters, 2002, 329, 349-353.	2.1	25
142	Suppression by protease-activated receptor-2 activation of gastric acid secretion in rats. European Journal of Pharmacology, 2002, 447, 87-90.	3.5	37
143	Effects of somatosensory cortical stimulation on expression of c-Fos in rat medullary dorsal horn in response to formalin-induced noxious stimulation. Journal of Neuroscience Research, 2002, 68, 479-488.	2.9	21
144	Capsazepine Partially Inhibits Neurally Mediated Gastric Mucus Secretion Following Activation Of Protease-Activated Receptor 2. Clinical and Experimental Pharmacology and Physiology, 2002, 29, 360-361.	1.9	27

#	Article	IF	Citations
145	Proteaseâ€activated receptorâ€2 (PARâ€2) in the rat gastric mucosa: immunolocalization and facilitation of pepsin/pepsinogen secretion. British Journal of Pharmacology, 2002, 135, 1292-1296.	5.4	51
146	Multiple roles for protease-activated receptor-2 in gastric mucosa. Inflammopharmacology, 2002, 10, 343-349.	3.9	5
147	Protease-activated receptor- 2 (PAR-2) : ç¥žçµŒç³»,æ¶ˆåŒ–å™¨ç³»ãŠã,ˆã³è¡€ç®¡ç³»ã«ãŠã‘ã‚‹å½¹å‰². Japanese Journal of Thrombosis 467-476.	0.1	1
148	Factor Xa-Evoked Relaxation in Rat Aorta: Involvement of PAR-2. Biochemical and Biophysical Research Communications, 2001, 282, 432-435.	2.1	48
149	Ex Vivo Evidence That the Phosphodiesterase Inhibitor IBMX Attenuates the Up-Regulation of PAR-2 in the Endotoxemic Rat Aorta. Thrombosis Research, 2001, 101, 513-515.	1.7	7
150	Specific Distribution of Sialic Acids in Animal Tissues As Examined by LCâ^'ESI-MS after Derivatization with 1,2-Diamino-4,5-Methylenedioxybenzene. Analytical Chemistry, 2001, 73, 5422-5428.	6.5	53
151	Peripheral PAR-2 triggers thermal hyperalgesia and nociceptive responses in rats. NeuroReport, 2001, 12, 715-719.	1.2	94
152	Lipopolysaccharide-induced subsensitivity of protease-activated receptor-2 in the mouse salivary glands in vivo. Naunyn-Schmiedeberg's Archives of Pharmacology, 2001, 364, 281-284.	3.0	14
153	In vivo evidence that protease-activated receptors 1 and 2 modulate gastrointestinal transit in the mouse. British Journal of Pharmacology, 2001, 133, 1213-1218.	5.4	71
154	Secondary somatosensory cortex stimulation facilitates the antinociceptive effect of the NO synthase inhibitor through suppression of spinal nociceptive neurons in the rat. Brain Research, 2001, 903, 110-116.	2.2	20
155	The protease-activated receptor-2 agonist induces gastric mucus secretion and mucosal cytoprotection. Journal of Clinical Investigation, 2001, 107, 1443-1450.	8.2	146
156	Protease-Activated Receptor (PAR), a Novel Family of G Protein-Coupled Seven Trans-membrane Domain Receptors: Activation Mechanisms and Physiological Roles. The Japanese Journal of Pharmacology, 2000, 82, 171-174.	1.2	71
157	Characterization of Protease-Activated Receptors in Rat Peritoneal Mast Cells. The Japanese Journal of Pharmacology, 2000, 82, 74-77.	1.2	30
158	Determination of Mucin in Salivary Glands Using Sialic Acids as the Marker by High-Performance Liquid Chromatography with Fluorometric Detection. Analytical Biochemistry, 2000, 283, 119-121.	2.4	13
159	Fluorometric Determination of Mucin-Type Glycoproteins by the Galactose Oxidase-Peroxidase Method. Analytical Biochemistry, 2000, 284, 87-92.	2.4	9
160	Proteinase-activated receptor-2 (PAR-2): regulation of salivary and pancreatic exocrine secretion in vivo in rats and mice. British Journal of Pharmacology, 2000, 129, 1808-1814.	5.4	88
161	Dual modulation by thrombin of the motility of rat oesophageal muscularis mucosae via two distinct protease-activated receptors (PARs): a novel role for PAR-4 as opposed to PAR-1. British Journal of Pharmacology, 2000, 131, 578-584.	5.4	37
162	Roles of urokinase type plasminogen activator in a brain stab wound. Brain Research, 2000, 887, 187-190.	2.2	21

#	Article	IF	Citations
163	Activation of Protease-Activated Receptor-2 (PAR-2) Triggers Mucin Secretion in the Rat Sublingual Gland. Biochemical and Biophysical Research Communications, 2000, 270, 298-302.	2.1	64
164	Somatosensory cortex stimulation-evoked analgesia in rats: Potentiation by no synthase inhibition. Life Sciences, 2000, 66, PL271-PL276.	4.3	21
165	Characterization of the protease-activated receptor-1-mediated contraction and relaxation in the rat duodenal smooth muscle. Life Sciences, 2000, 67, 2521-2530.	4.3	29
166	Activation of protease-activated receptor-2 triggers salivation. The Japanese Journal of Pharmacology, 1999, 79, 92.	1.2	2
167	Enhancement of vascular permeability by specific activation of protease-activated receptor-1 in rat hindpaw: a protective role of endogenous and exogenous nitric oxide. British Journal of Pharmacology, 1999, 126, 1856-1862.	5.4	41
168	Modulation by protease-activated receptors of the rat duodenal motility in vitro : possible mechanisms underlying the evoked contraction and relaxation. British Journal of Pharmacology, 1999, 128, 865-872.	5.4	69
169	Proteinase activated receptor 2: role of extracellular loop 2 for ligand-mediated activation. British Journal of Pharmacology, 1999, 128, 1105-1113.	5.4	52
170	Increased vascular permeability by a specific agonist of proteaseâ€activated receptorâ€2 in rat hindpaw. British Journal of Pharmacology, 1998, 125, 419-422.	5.4	114
171	Penetration of cisplatin into mouse brain by lipopolysaccharide. Toxicology, 1998, 130, 107-113.	4.2	41
172	Roles of nitric oxide and prostaglandins in the increased permeability of the blood-brain barrier caused by lipopolysaccharide. Environmental Toxicology and Pharmacology, 1998, 5, 35-41.	4.0	35
173	Cross tolerance to environmental stress and endotoxin. Life Sciences, 1998, 62, PL327-PL333.	4.3	4
174	SPECIAL REPORT Evidence that endogenous nitric oxide modulates plasma fibrinogen levels in the rat. British Journal of Pharmacology, 1996, 117, 236-237.	5.4	28
175	Attenuation by prolonged nitric oxide synthase inhibition of the enhancement of fibrinolysis caused by environmental stress in the rat. British Journal of Pharmacology, 1996, 119, 346-350.	5.4	20
176	1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one reverses the inhibition by sodium nitroprusside of thrombin-induced platelet aggregation in the rat. Thrombosis Research, 1996, 82, 543-545.	1.7	1
177	Kyotorphin synthetase activity in rat adrenal glands and spinal cord. Peptides, 1996, 17, 407-411.	2.4	8
178	Central antinociceptive effect of l-ornithine, a metabolite of l-arginine, in rats and mice. European Journal of Pharmacology, 1996, 296, 23-31.	3.5	12
179	Lipopolysaccharide-induced platinum accumulation in the cerebral cortex after cisplatin administration in mice: Involvement of free radicals. Environmental Toxicology and Pharmacology, 1996, 2, 321-326.	4.0	13
180	NG-Nitro-l-arginine methyl ester and Î±-methyl-l-ornithine inhibit kyotorphin synthetase from rat brain. Peptides, 1995, 16, 1317-1319.	2.4	5

#	Article	IF	Citations
181	Studies on pain modulation by neuroactive amino acids VHI: Antinociceptive mechanisms of L-ornithine, a metabolite of L-arginine.. The Japanese Journal of Pharmacology, 1994, 64, 180.	1.2	1
182	Effect of topical administration of <scp>l</scp>â€arginine on formalinâ€induced nociception in the mouse: a dual role of peripherally formed NO in pain modulation. British Journal of Pharmacology, 1994, 112, 547-550.	5.4	139
183	Comparison of antinociception induced by supraspinally administered <scp>l</scp>â€arginine and kyotorphin. British Journal of Pharmacology, 1994, 112, 817-822.	5.4	15
184	The noradrenaline precursor <scp>l</scp>â€threoâ€3,4â€dihydroxyphenylserine exhibits antinociceptive activity via central Î±â€adrenoceptors in the mouse. British Journal of Pharmacology, 1994, 111, 503-508.	5.4	13
185	Possible involvement of oxygen-derived free radicals in abnormal hemostasis induced by SART stress (repeated cold stress) in laboratory animals. Thrombosis Research, 1993, 72, 321-331.	1.7	8
186	L-Tyrosine-induced antinociception in the mouse: involvement of central Î´-opioid receptors and bulbo-spinal noradrenergic system. European Journal of Pharmacology, 1993, 233, 255-260.	3.5	7
187	<scp>l</scp>â€Arginine exerts a dual role in nociceptive processing in the brain: involvement of the kyotorphinâ€Metâ€enkephalin pathway and NOâ€cyclic GMP pathway. British Journal of Pharmacology, 1993, 109, 73-79.	5.4	112
188	Characterization of platelet hypofunctions in rats under SART stress (repeated cold stress). Thrombosis Research, 1993, 69, 197-207.	1.7	9
189	<scp>l</scp>â€Leucylâ€<scp>l</scp>â€arginine, naltrindole and <scp>d</scp>â€arginine block antinociception elicited by <scp>l</scp>â€arginine in mice with carrageeninâ€induced hyperalgesia. British Journal of Pharmacology, 1992, 107, 1096-1101.	5.4	69
190	Antinociceptive effect of L-arginine on the carrageenin-induced hyperalgesia of the rat: possible involvement of central opioidergic systems. European Journal of Pharmacology, 1992, 218, 153-158.	3.5	67
191	Blood Coagulation and Fibrinolysis in SART-Stressed (Repeated Cold-Stressed) Rats and Drug Effects on the Altered Hemostatic Parameters. The Japanese Journal of Pharmacology, 1991, 56, 403-412.	1.2	0
192	Changes in CNS Levels of Serotonin and Its Metabolite in SART-Stressed (Repeatedly Cold-Stressed) Rats. The Japanese Journal of Pharmacology, 1991, 56, 101-104.	1.2	8
193	Changes in CNS Levels of Serotonin and Its Metabolite in SART-Stressed(Repeatedly) Tj ETQq1 1 0.784314 rgBT /Overlock 10 Tf 50 262	1.2	27
194	Blood Coagulation and Fibrinolysis in SART-Stressed (Repeated Cold-Stressed) Rats and Drug Effects on the Altered Hemostatic Parameters.. The Japanese Journal of Pharmacology, 1991, 56, 403-412.	1.2	11
195	A Characteristic Pattern of Active Avoidance Behavior in SART-Stressed Rats. The Japanese Journal of Pharmacology, 1989, 49, 436-440.	1.2	2
196	Impairment of Passive Avoidance Performance in SART-Stressed Mice and the Action of Drugs. The Japanese Journal of Pharmacology, 1989, 49, 111-117.	1.2	2
197	Subsensitivity to substance P in SART-stressed mice.. The Japanese Journal of Pharmacology, 1989, 49, 293-296.	1.2	3
198	A characteristic pattern of active avoidance behavior in SART-stressed rats.. The Japanese Journal of Pharmacology, 1989, 49, 436-440.	1.2	4

#	Article	IF	Citations
199	Impairment of passive avoidance performance in SART-stressed mice and the action of drugs.. The Japanese Journal of Pharmacology, 1989, 49, 111-117.	1.2	17
200	Changes in platelet count and related parameters in SART-stressed mice and the action of administered neurotropin.. The Japanese Journal of Pharmacology, 1988, 47, 349-356.	1.2	15
201	Mechanism of the Analgesic Effect of Neurotropin. The Japanese Journal of Pharmacology, 1988, 48, 165-173.	1.2	32
202	The Abnormal Open-Field Behavior of SART-Stressed Rats and Effects of Some Drugs on It. The Japanese Journal of Pharmacology, 1988, 48, 479-490.	1.2	31
203	Changes in Platelet Count and Related Parameters in SART-Stressed Mice and the Action of Administered Neurotropin. The Japanese Journal of Pharmacology, 1988, 47, 349-356.	1.2	0
204	Electrocorticogram in rats loaded with SART stress (repeated cold stress).. The Japanese Journal of Pharmacology, 1987, 45, 365-372.	1.2	20
205	Electrocorticogram in Rats Loaded with SART Stress (Repeated Cold Stress). The Japanese Journal of Pharmacology, 1987, 45, 365-372.	1.2	2
206	Effects of Neurotropin and other drugs on changes in brain and plasma catecholamine content in SART-stressed rats. The Japanese Journal of Pharmacology, 1987, 43, 153.	1.2	5
207	Changes of Total Acetylcholine Content and the Activity of Related Enzymes in SART (Repeated) Tj ETQq1 1 0.784314 rgBT /Overlock	1.2	25
208	Changes of Tissue Blood Flow in Mice Loaded with SART (Repeated Cold) Stress or Restraint and Water Immersion Stress and the Effect of Administered Neurotropin. The Japanese Journal of Pharmacology, 1986, 41, 69-79.	1.2	37
209	Effect of ginseng-20S-prosapogenin on tissue blood flow measured by the hydrogen clearance method in sympathicotonic- or parasympathicotonic-type stressed mice.. Journal of Pharmacobio-dynamics, 1985, 8, 1068-1072.	0.5	1